Aerocrine Receives FDA Clearance for NIOX VERO Wireless Enhancement

Aerocrine AB has received U.S. Food and Drug Administration (FDA) clearance for its FeNO measuring device to operate wirelessly with BlueTooth technology.

The approval will enable the company’s NIOX VERO device to use BlueTooth wireless technology to send FeNO measurements and patient data to healthcare providers’ computers. This cordless enhancement allows the device to go with a healthcare provider to a patient regardless of setting, either in an examination room, a pulmonary function lab or other setting. The clearance also allows the NIOX VERO to wirelessly transmit patient data to the computer for storage by the healthcare providers on the NIOX Patient software, Aerocrine’s propriety data repository or other electronic medical record software the healthcare providers may be using.

NIOX VERO is Aerocrine’s next generation device for measuring Fractional Nitric Oxide (FeNO) levels in a clinical setting. This measurement has been found to be cost effective to aid in the diagnosis and management of allergic airway inflammation such as with asthma.

Aerocrine launched the NIOX VERO in the U.S. market in January. Company bigwigs said the Bluetooth enhancement will make it easier for physicians and patients to benefit from the use of FeNO measurement as part of their asthma diagnosis and management. The NIOX VERO now is completely portable; its battery can hold a full day charge and can be brought to the patient in the examining room instead of the patient having to go to the device.

Aerocrine AB is a Swedish developer of devices to treat patients with inflammed airways. The company operates subsidiaries in the United States, Germany, Switzerland and the United Kingdom. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007.